The FDA enforcement report dated 9 September lists a Class II recall by Baxter Healthcare of vancomycin injection USP in 0.9% sodium chloride, 1 g per 200 mL (5 mg/mL), in GALAXY single-dose containers. The stated reason is deviation from current good manufacturing practice (CGMP). The recall is ongoing.
A Class II recall means the FDA judges that use may cause temporary or medically reversible harm, or that serious harm is remote. The report does not describe a specific defect, contamination or patient injury, so there is no clinical signal here beyond the manufacturing finding.
The practical effect is on supply. Hospitals that rely on premixed bags may need pharmacy-compounded vancomycin instead, which brings its own risks of dose and dilution error. The recall is a US action; whether this product reaches Indian hospitals is not stated.
- Ask pharmacy whether affected lots are on your shelves
- If switching to compounded vancomycin, check concentration and infusion rate on the label
- Keep infusion at no more than 10 mg/min to limit infusion reactions
- Continue trough or AUC-guided monitoring as usual
Why it matters
The risk to patients is more likely to come from supply substitutions than from the recalled bags themselves.
Don't overread it
A CGMP recall is a manufacturing finding, not evidence that patients were harmed.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for infectious diseases, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free